House lawmakers' latest target in addressing high drug prices: Generic competition

The House Committee on Energy & Commerce Health subcommittee held a hearing to consider measures to address the problem of high prescription drug costs. (Pixabay)

Tactics used by drug companies to delay generic competition are the target of a collection of bills being considered by lawmakers in the latest efforts to address the high price of precision drugs.

“For too long, people have been subjected to the abuse of the patent system by pharmaceutical companies and generic companies entering into agreements and employing tactics that block the competition and keep prices high,” Rep. Anna Eshoo, D-Calif., during a hearing by the House Committee on Energy & Commerce Health subcommittee on Wednesday.

The subcommittee had seven potential measures to consider, including bills aimed at addressing drug company tactics used to restrict access by generic drug makers to their samples or to pay generic competitors with exclusivity to delay the release of a generic competitor.

Featured Webinar

Patient experience and the bottom-line impact on a practice

Practices that deliver exceptional experience often demonstrate strong financial performance and efficient operations. Join us to learn how to identify the most impactful connections between patient experience and financial performance, how to measure, track and improve patient experience as it relates to the bottom line, and identify patient experience measures that affect financial performance.

They are also eyeing measures to amend the Purple and Orange books used by the Food and Drug Administration to inform manufacturers about active patents.

RELATED: Trump administration proposal would allow Part D plans to negotiate prices of drugs in 'protected' classes

While the different bills up for consideration in committee would employ different tactics, each would be aimed at introducing competition into the market sooner, moving drugs to the market more quickly and lowering costs, Eshoo said.

It’s the latest in growing interest by Congress to address the problem of high prescription drug costs, prioritized by the Trump administration with the release of a prescription drug price blueprint last May. It’s also a shift in focus from efforts which, so far, have largely focused on the lack of price transparency, on the role of payers such as Medicare in negotiating prices, the impact of overseas markets and on hidden financial arrangements involving pharmacy benefit managers.

See the hearing below.



Suggested Articles

CMS announced it will offer the COVID-19 vaccine to Medicare beneficiaries at no cost to patients and issued new add-on payments for virus treatments.

HHS will give out $333 million in incentive payments to nursing homes who lowered their COVID-19 case and death counts in September.

Nearly half of employees have deferred care amid the pandemic, according to a new survey from Willis Towers Watson.